Clinical Research · uk
When Does Bloating Warrant Investigation for Cancer? UK Trial of More Than 20,000 Patients to Evaluate AI and Protein Blood Tests
Could one or two tubes of blood help GPs identify patients who need urgent investigations earlier? STRIDE-RCT will bring multi-cancer blood tests into routine consultations to assess whether they can improve referral decisions; trial results on their diagnostic benefit are not yet available.
Persistent bloating or abdominal discomfort can have many causes, but may also be a warning sign of cancer that is not yet apparent. For GPs, the challenge is identifying people who need prompt investigation among those with common, vague symptoms. On November 4, the UK announced the launch of STRIDE-RCT, which will assess whether blood tests can provide more reliable clues to support these decisions at at least 200 GP practices in England.
Led by the University of Birmingham, the platform trial plans to enrol more than 20,000 NHS patients in the UK aged over 45 who seek care for abdominal symptoms, with up to £8.49 million in government funding. The study focuses on patients who already have symptoms and are attending outpatient consultations, rather than population-wide screening of people without symptoms. Its scope includes bowel, pancreatic, stomach, liver and ovarian cancers, as well as various other cancers.
According to the university, most of the tests being evaluated require just one or two additional tubes of blood during a routine blood draw to look for signals of multiple cancers and attempt to identify where in the body those signals may originate. The technologies covered by the trial include artificial intelligence and measurement of proteins in the blood. However, the announcement did not specify which markers each test uses, how the AI models were trained, or how they performed in existing validation data, so their accuracy cannot yet be compared on this basis.
Test results will be used alongside doctors’ clinical judgement. A positive result may help doctors and patients decide whether an urgent referral is needed, but cannot establish a cancer diagnosis on its own. Reporting by The Pharmacist also emphasised that the study aims to determine whether blood tests can help patients who need further investigation receive appropriate tests earlier, rather than provide a diagnosis from a single blood draw.
There are pressures on both sides: some patients with cancer may face delays in investigation because their symptoms are unclear, while many people referred urgently ultimately do not have cancer. Co-chief investigator Aneel Bhangu, a professor at the University of Birmingham, said blood tests might help doctors distinguish between these two groups, but sufficient evidence must be obtained before widespread adoption across the NHS.
The trial will also include practices in inner-city, rural, coastal and socioeconomically disadvantaged communities to make its findings more representative of different patient groups. This brings the evaluation into real-world primary care: whether the tests are useful depends on whether adding them to routine consultations helps doctors make better decisions about subsequent care.
The announcement concerns the launch of the trial. No figures have yet been provided for sensitivity or false-positive or false-negative rates, and there is no evidence that these tests can already shorten the time to diagnosis or improve survival. Even if cancer signals can be detected in the blood, it remains necessary to demonstrate that this information is sufficient to improve care and to clarify the additional investigations or delays that incorrect results could cause. The results of STRIDE-RCT will provide an important basis for assessing whether to expand adoption within the NHS.